• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » UPDATE: CeQur closes $30 million Series A round with $10 million injection

UPDATE: CeQur closes $30 million Series A round with $10 million injection

January 5, 2010 By MassDevice staff

CeQur SA completed a $30 million Series A funding round with a $10 million injection from a group of existing backers.

The Swiss company, which houses its U.S. operations in Marlborough, Mass., said it plans to use the funds to clear regulatory hurdles in Europe for its subcutaneous insulin patch for Type 2 diabetes. The investment group includes BMC Ventures A/S, Endeavour Vision SA, Schroder & Co. Bank AG and Venture Incubator AG.

Jay Warner, CeQur’s senior vice president for sales and marketing, told MassDevice that the company anticipates launching the product in the EU sometime after the first quarter of 2010. The company has had a good dialogue with Food & Drug Administration officials about getting the device cleared for sale in the U.S., but Warner said a time frame for a state-side launch is “not determined.” CeQur will apply for 510(k) premarket notification clearance, he added.

The company’s lead product is a wearable insulin patch that provides a three-day supply of basal insulin delivery and on-demand bolus insulin, which the user can deploy with the touch of a button. Although the company is initially targeting Type 2 diabetics, Warner said he believes there could be other applications for the patch, as CeQur looks to leverage it into a platform technology.

While the firm is based in Switzerland, Warner said the bulk of CeQur’s staff is located at the company’s Marlborough operation, with slightly more than 20 employees there. The firm has not built a direct sales force yet and is still weighing its options on distribution partners, he said.

“I think we have a product that is very viable, from a direct sales and marketing perspective,” Warner said.

CeQur is led by James Peterson, the former CEO of Braintree, Mass.-based Haemonetics Corp. (NYSE:HAE).

In October, CeQur named Eric Milledge, the former president of LifeScan Inc., chairman of the board.

Milledge spent more than 34 years at Johnson & Johnson Corp. (NYSE:JNJ), rising to group president for LifeScan, which produces blood glucose meters, test strips and diabetes management software. The subsidiary employs more than 2,500 workers globally.

“We think one of our strengths as a company is the depth of our bench,” Warner said, noting that the company was steeped in experience with both medical devices and diabetes management.

Filed Under: Business/Financial News, News Well Tagged With: Insulin Management

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy